January 11, 2022
A year after the Seventh Circuit ruled that fewer than 40 workers in an overtime suit may be enough for class certification, attorneys told Law360 the decision highlights other factors to consider when assessing whether a class action meets a key requirement in a category called numerosity.
August 04, 2021
A Fourth Circuit panel hit the reset button Wednesday on the certification of a class of 35 drug wholesalers suing Merck and Glenmark for allegedly delaying generic entry of Merck cholesterol drug Zetia, remanding the antitrust case so a Virginia federal judge can reconsider her "faulty logic."
May 06, 2021
The Fourth Circuit was chatty Thursday while mulling whether to uphold or overturn the certification of what pharmaceutical giants Merck and Glenmark have called an "extremely small" class of drug buyers in a fight over the delayed release of a cholesterol drug.
April 08, 2021
Merck and Glenmark have told the Fourth Circuit that a newly issued Ninth Circuit decision upending class certification for buyers alleging price-fixing of canned tuna "directly supports" undoing certification of drug wholesalers accusing the two drugmakers of blocking a generic form of cholesterol drug Zetia.
January 05, 2021
Drugmakers Merck and Glenmark have asked the Fourth Circuit to reverse the class certification of direct buyers of cholesterol drug Zetia, stating the named plaintiffs were unfit to represent the class and the other members' circumstances did not warrant class status.
November 16, 2020
Direct buyers of Zetia got their wish granted Monday when the Fourth Circuit agreed to speed along a challenge to their class certification in a case accusing drugmakers Merck and Glenmark of blocking a generic form of the cholesterol drug from making it to market.
November 12, 2020
In a bid to minimize delays, direct buyers of Zetia have urged the Fourth Circuit to expedite a challenge to their class certification in a case accusing drugmakers Merck and Glenmark of violating antitrust law by blocking a generic form of the cholesterol medication.
November 03, 2020
The Fourth Circuit is going to hear a challenge mounted by pharmaceutical giants Merck and Glenmark to the certification of what they have called an "extremely small" class of drug buyers alleging the duo conspired to keep a generic version of the cholesterol drug Zetia off the market.